Re: Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA®
"I think you're diluting yourself. I'll believe it when I see it. "
Not sure what you mean by that statement. First, I'm no longer in DVAX. But the fact is, hepislva B uptake is so slow, they realize they cannot service the required $s for the oncology trials without running out of cash, or having to do a secondary at these very depressed prices. They need to take out big time expenses, raise capital, and pay down debt, ramp hepislav B sales to get financially back in order. That's what these moves are designed to do. Too late? maybe.